The company expects to make the updated Spikevax available to U.S. patients in time for the 2025-26 respiratory virus season.

The new memos from the Food and Drug Administration show how the agency’s vaccine chief, Dr. Vinay Prasad, personally ...

RSV, meningococcal, and chikungunya vaccine recommendations from the previous ACIP panel are now official policy.

Variant NB.1.8.1 accounted for 0% of U.S. cases in April. By mid-June, it was estimated to be the cause of around 37% of ...

Public health community has raised concerns about how the newly-picked vaccine panel may influence decisions going forward.